Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company is expected to benefit from the continuous growth of its cartridge bottle components, with projected revenue growth in 2026 [1][4]. - The global AI-enabled drug development market is anticipated to grow from USD 11.9 billion in 2023 to USD 74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6% [3]. - The establishment of a wholly-owned subsidiary and investment in Suzhou Kema Biotechnology are seen as strategic moves to enhance the company's capabilities in AI drug development [2][3]. Summary by Sections Investment Rating - The target price is set at RMB 69.60, reflecting a price-to-earnings (PE) ratio of 85x for 2026, which is a premium compared to the industry average [5][7]. Company Strategy - The company has made significant investments in AI drug development, including the establishment of an AI pharmaceutical committee and partnerships with technology firms [1][3]. - The company aims to leverage its extensive customer base of over 1,000 pharmaceutical companies across more than 40 countries to facilitate the commercialization of its AI-enabled drug development initiatives [2][3]. Financial Projections - Revenue is projected to reach RMB 896.34 million in 2026, with a year-on-year growth of 17.17% [11]. - The net profit attributable to the parent company is expected to be RMB 134.46 million in 2026, reflecting a 24.44% increase from the previous year [11]. - The company anticipates a stable performance in its core business of pharmaceutical rubber stoppers, with revenue growth expected to be between 5% and 15% [4].
华兰股份（301093）：依托药企客户优势，深度布局AI制药